Spinal Muscular Atrophy (SMA) Clinical Trials

16 recruiting

Frequently Asked Questions

Common questions about Spinal Muscular Atrophy (SMA) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Not Applicable

HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness

Spinal Muscular Atrophy (SMA)
Teachers College, Columbia University20 enrolled1 locationNCT07488338
Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA)
argenx60 enrolled17 locationsNCT07287982
Recruiting
Phase 3

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals175 enrolled32 locationsNCT05335876
Recruiting

Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases

Muscular DystrophiesSpinal Muscular Atrophy (SMA)Myopathies
IRCCS Eugenio Medea120 enrolled2 locationsNCT06666816
Recruiting

Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System

Spinal Muscular Atrophy (SMA)
Medstar Health Research Institute200 enrolled1 locationNCT07223489
Recruiting
Not Applicable

Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers

Myotonic DystrophyMuscular DystrophyCharcot-Marie-Tooth+1 more
Institut de Myologie, France30 enrolled1 locationNCT07321977
Recruiting
Not Applicable

Long Read Analysis in Spinal Muscular Atrophy - LOREASI

Spinal Muscular Atrophy (SMA)
University Hospital, Rouen27 enrolled1 locationNCT07332702
Recruiting
Not Applicable

Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening

Duchenne Muscular Dystrophy (DMD)Spinal Muscular Atrophy (SMA)
Centre Hospitalier Universitaire de Liege100 enrolled1 locationNCT07286565
Recruiting
Phase 3

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Spinal Muscular Atrophy (SMA)
Lantu Biopharma15 enrolled1 locationNCT07265232
Recruiting
Not Applicable

The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder

Upper ExtremityMuscular Dystrophy, DuchenneNeuromuscular Diseases (NMD)+6 more
Seoul National University Hospital30 enrolled1 locationNCT06363357
Recruiting
Not Applicable

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

Cerebral Palsy (CP)Duchenne Muscular Dystrophy (DMD)Spinal Muscular Atrophy (SMA)
University of Copenhagen8 enrolled1 locationNCT07254988
Recruiting
Not Applicable

Robot-assisted Training

Spinal Muscular Atrophy (SMA)
Peking University Third Hospital13 enrolled1 locationNCT06648486
Recruiting
Not Applicable

Safety and Tolerability of Low Motoneuron Stimulation Via Transcranial Magnetic Stimulation in Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA)
Charitable Foundation Children with Spinal Muscular Atrophy20 enrolled1 locationNCT06977269
Recruiting

Adult SMA Research and Clinical Hub

Spinal Muscular Atrophy (SMA)
Newcastle-upon-Tyne Hospitals NHS Trust600 enrolled18 locationsNCT06978985
Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals700 enrolled99 locationsNCT04174157
Recruiting
Phase 1Phase 2

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

Spinal Muscular Atrophy (SMA)
Biocad40 enrolled7 locationsNCT05747261